Pro and con: High-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management

American Journal of Cardiology

Volumn 87, Issue 5 SUPPL. 1, 2001, Pages 2-7

  Assmann, Gerd ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ACCURACY; ANALYTIC METHOD; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY DISEASE; HEART INFARCTION; HUMAN; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0035825927     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9149(01)01448-5     Document Type: Conference Paper

References (18)

1. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention
2. Beyond LDL cholesterol reduction
3. Raising low levels of high-density lipoprotein cholesterol is an important target of therapy
4. The Münster Heart Study (PROCAM): Results of follow-up at 8 years
5. Role of triglycerides in coronary artery disease: Lessons from the Prospective Cardiovascular Münster Study
6. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men
7. Coronary heart disease: Reducing the risk
8. Coronary heart disease: Reducing the risk: A worldwide view
9. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
10. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
11. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
12. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels
13. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
14. Prevention of coronary heart disease by raising high-density lipoprotein cholesterol?
15. Short-term prognostic value of lipid measurements for coronary events in patients with angina pectoris
16. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
17. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
18. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) Study